Diuretics Global Market Report 2024

The diuretics market size has grown steadily in recent years. It will grow from $0.71 billion in 2023 to $0.75 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth witnessed during the historical period can be attributed to a variety of factors, including the widespread occurrence of chronic diseases, a progressively aging population, the impact of clinical guidelines, continuous advancements in pharmaceutical innovation, and the escalating prevalence of obesity.

The diuretics market size is expected to see steady growth in the next few years. It will grow to $0.88 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The anticipated growth in the forecast period can be attributed to various factors, including the rising incidence of hypertension and heart failure, the expansion of emerging markets, government healthcare initiatives, and a growing focus on preventive healthcare. Notable trends in the forecast period include the adoption of personalized medicine, the exploration of innovative drug development approaches, the integration of telehealth and remote monitoring, and the utilization of digital health solutions to improve patient care and overall outcomes.

The diuretics market is on an upward trajectory due to the increasing prevalence of renal and kidney disorders. When the kidneys fail to function properly, there is a heightened demand for diuretic drugs, commonly known as water pills, to ensure the proper flow of urine. Lifestyle changes, including the consumption of unhealthy, mineral-rich foods, are contributing to the rise in kidney disorders. In 2021, the Centers for Disease Control and Prevention reported that around 37 million people, equivalent to 15% of US adults, were afflicted by chronic kidney diseases. This surge in cases of renal and kidney disorders is a significant driving force behind the growth of the diuretics market.

The main categories of diuretics encompass osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides and thiazide-like diuretics, and aldosterone antagonists. Osmotic diuretics prevent the reabsorption of water and sodium and are typically administered intravenously as pharmacologically inactive compounds. They are employed in the treatment of conditions like hypertension, glaucoma, heart failure, and kidney stones. These diuretics are distributed through various channels, including hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies.

The diuretics market research report is one of a series of new reports that provides diuretics market statistics, including diuretics industry global market size, regional shares, competitors with a diuretics market share, detailed diuretics market segments, market trends and opportunities, and any further data you may need to thrive in the diuretics industry. This diuretics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diuretics market is anticipated to be fueled by the increasing incidence of cardiac disorders. Cardiac disorders encompass a range of medical conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and arrhythmias. Diuretics play a pivotal role in managing cardiovascular diseases by reducing excess bodily fluids, lowering blood pressure, and easing the workload on the heart. This, in turn, improves the overall management of conditions such as hypertension and congestive heart failure. For example, as of May 2023, the Centers for Disease Control and Prevention reported that coronary artery disease was responsible for 375,476 deaths in 2021, with a significant proportion affecting adults under the age of 65. Therefore, the growing prevalence of cardiac disorders is a prominent driver of the diuretics market.

The stringent regulatory policies governing the diuretics market pose certain limitations. These regulations outline requirements for drug manufacturing, processing, and packaging, necessitating compliance with various standards, including the FDA's CGMP regulations, European Medicines Agency Regulations, and WHO Guidelines. For instance, the FDA's Current Good Manufacturing Practice (CGMP) regulations in the USA impose strict guidelines for drug application, licensing, manufacturing processes, and finished pharmaceutical product requirements. These regulatory constraints have a dampening effect on market growth.

To address challenges in diuretic drug delivery, innovative technology known as oral nanoparticle delivery technology has been developed. This technology aims to enhance the effectiveness of diuretic drugs by improving their pH and intestinal permeability, addressing issues related to low water solubility and bioavailability. For example, nanotechnology-based drug delivery systems are being used to administer drugs like amlodipine and isradipine, which have low bioavailability and are sensitive to light. These advancements result in improved drug stability and bioavailability. Companies like Nanomerics, a pharmaceutical nanotechnology company, are actively researching MET (Molecule Envelop Technology) Nanoparticles Oral Delivery. Additionally, in January 2021, nanomaterial-based drug delivery allowed doxorubicin, a highly toxic drug, to be delivered directly to tumor cells using liposomes (Doxil) without negatively impacting the heart or kidneys.

Major companies are introducing innovative products like FUROSCIX to expand their global presence and gain a competitive edge. FUROSCIX is a subcutaneous furosemide injection that offers an alternative method for administering diuretic medication to manage fluid overload in patients with heart failure. For instance, scPharmaceuticals Inc. announced FDA approval for FUROSCIX in October 2022, specifically for treating congestion caused by fluid overload in adults with New York Heart Association Class II/III chronic heart failure. FUROSCIX provides at-home IV-equivalent diuresis through the FUROSCIX Infusor and is the first and only FDA-approved subcutaneous loop diuretic.

In November 2022, Novo Integrated Sciences Inc., a healthcare company, and Clinical Consultants International LLC, a hospital consulting firm, entered into a consulting agreement with Sarfez Pharmaceuticals Inc. for an FDA-approved edema treatment targeting patients with heart failure and renal disease. Utilizing their extensive network of hospitals, physicians, and independent pharmacies, CCI and the Novo team will collaborate with Sarfez on the marketing and distribution of the commercially available SOAANZ treatment. Sarfez Pharmaceuticals Inc. is a pharmaceutical research and development company.

Major companies operating in the diuretics market include Merck & Co. Inc., Meda Manufacturing GmbH, Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Aton Pharma Inc., Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi-aventis U.S. LLC, Centaur Pharmaceuticals Pvt Ltd., Validus Pharmaceuticals LLC, Actavis Generics, Paddock Laboratories LLC, Perrigo Pharmaceutical Company, H. Lundbeck Inc., Oak Pharmaceuticals Inc., Akron Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Aurobindo Pharma Limited, IPCA Laboratories Limited, Jubilant Cadista Pharmaceuticals Limited, Mylan N.V., Princeton Laboratories Inc., Sciegen Pharma Limited, Unichem Laboratories Limited, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd., F Hoffmann-La Roche Ltd., Fresenius Kabi AG, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

North America was the largest region in the diuretics market in 2023. The Middle East is expected to be the fastest-growing region in the diuretics market during the forecast period. The regions covered in the diuretics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diuretics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The diuretics market consists of sales of diuril, microzide, and indapamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.